Malaysia has been chosen as a trial site for another made-in-China Covid-19 vaccine, this time by Shenzhen Kangtai Biological Products Co Ltd.
According to Health Ministry director-general Dr Noor Hisham Abdullah, the phase three clinical trials were approved by the National Pharmaceutical Regulatory Agency on May 28.
The product - known by its technical name as SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL - will be administered by eight research centres and will involve 3,000 participants.
Noor Hisham said the study will take between 15 to 19 months. Other countries participating in the trials are Colombia, Argentina, Pakistan, the Philippines and Ukraine.
The vaccine received emergency use approval from the Chinese government on May 14. Apart from manufacturing its own vaccines, Kangtai has received exclusive rights to manufacture the Oxford/Astrazeneca vaccine in China.
Yong Tai Bhd subsidiary YTB Healthcare Sdn Bhd will be in charge of handling the clinical trials. It will be the first private company in the country to conduct a phase three clinical trial for a Covid-19 vaccine.
Currently, Malaysia's available vaccine portfolio consists of vaccines by Pfizer, AstraZeneca and Sinovac.
As of yesterday, approximately eight percent of the adult population in Malaysia has received at least one dose of a Covid-19 vaccine. - Mkini
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.